Wednesday, July 8, 2026

Patent intelligence · US

US 7346387

Methods for improved selectivity in photo-activation and detection of molecular diagnostic agents

granted A61KA61K41/008A61K49/0017A61K49/0039
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 2
Applicant portfolio 29
Patent details — US 7346387
Jurisdiction
US
Status
granted
Grant date
Mar 18, 2008
Expiration
Mar 13, 2028
Claims
19
CPC classes
A61K, A61K41/008, A61K49/0017, A61K49/0039
View on Google Patents ↗

Quick answer

US 7346387 (Methods for improved selectivity in photo-activation and detection of molecular diagnostic agents) is held by Provectus Devicetech, Inc.. Status: granted. Granted Mar 18, 2008. Expires Mar 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61K, A61K41/008, A61K49/0017, A61K49/0039, A61K49/0043

More from Provectus Devicetech, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Expires Jul 31, 2045

    granted
  2. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Expires Oct 31, 2044

    granted
  3. US 12064507

    Composition and method for oral treatment of leukemia

    Provectus Pharmatech, Inc. · Expires Aug 15, 2044

    granted
  4. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Expires May 2, 2044

    granted
  5. US 11975106

    Uses of halogenated xanthenes in oncology and virology

    Provectus Pharmatech, Inc. · Expires May 2, 2044

    granted
  6. US 11938182

    Halogenated xanthenes as vaccine adjuvants

    Provectus Pharmatech, Inc. · Expires Mar 21, 2044

    granted
  7. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Provectus Pharmatech, Inc. · Expires Aug 25, 2042

    granted
  8. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Expires Aug 18, 2042

    granted

Frequently asked questions

What is US patent 7346387?

US 7346387 (Methods for improved selectivity in photo-activation and detection of molecular diagnostic agents) is held by Provectus Devicetech, Inc.. Status: granted. Granted Mar 18, 2008. Expires Mar 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7346387?

Provectus Devicetech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.

When does US 7346387 expire?

Our index shows an expiration date of Mar 13, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.